# Professor 1: Chair, bioinformatics (medium)

## Scores
A: 8.5
B: 8.0
C: 7.8
D: 8.5
E: 8.4
F: 8.1
G: 7.6
H: 7.8
I: 9.0
J: 8.0
total: 81.7/100

## Rationale (<=3 sentences each item)
A: The problem statement is now appropriately framed as a wet-lab triage benchmark rather than a deployable detector, which substantially improves scientific defensibility. The gap is specific: region-level, single-position viral hotspot prioritization lacks standardized multi-pathogen benchmarking across biological information types. A small deduction remains because the introduction still occasionally gestures toward "which method should be applied" in a way that can sound more operationally prescriptive than the negative LOPO/HBFWS evidence supports.

B: The related work is broad and current, covering viral surveillance, hotspot methods, DMS, PLMs, VEP benchmarks, cancer-genomics analogues, algorithm selection, and benchmarking bias. The distinction from ProteinGym, EVEREST, ViroGym, EVEscape, Nextstrain, PANGO, and MutClust is mostly clear and task-based rather than overstated. Deductions are for density and some self-positioning that still leans on "broadest" and "no counterpart" claims that require careful wording because adjacent viral VEP benchmarks are rapidly moving.

C: The methodology is ambitious and mostly well specified: 3-layer ground truth, 20 scoring formulas, 39 detector variants, MCC-based Stage 2 evaluation, cluster bootstrap, ANCOVA, Bayesian checks, Friedman, LOPO, vaccine-escape enrichment, and nested-LOPO ablations. The main methodological weakness is not hidden but real: Layer A is heterogeneous, partly frequency/escape-coupled, curated by one team, and the 11-pathogen panel is small for adaptive inference. I also deduct for complexity of multiple Stage 3 protocols and EqualWeight variants, which are explained but raise audit burden.

D: The scale is strong for a dissertation in this niche: 11 RNA-virus surface glycoproteins, 8,580 evaluation cells, 14 detector families, 10 information families, and several robustness/audit layers. The panel spans diverse viral biology and sequence regimes, and the work goes well beyond a single-pathogen method paper. The deduction is that the apparent computational scale exceeds the biological replication scale: only 11 main pathogens, 6 with DMS Layer C, and 3 with curated escape validation.

E: The interpretation is unusually disciplined after the reframe: LOPO 0/11 is treated as null-consistent, Friedman p=0.990 as absence of a universal winner, and HBFWS/Cycle 7B as bounded negative evidence. The HIV-1 enrichment is correctly separated from H3N2 self-consistency and SARS-CoV-2 exploratory support. Some discussion still risks overloading readers with many auxiliary audits, but the central claim hierarchy is now scientifically coherent.

F: The novelty is good: a region-level viral hotspot benchmark comparing biological information sources across pathogens is a meaningful contribution distinct from per-variant fitness prediction benchmarks. The quantified scoring-by-pathogen interaction and the external escape-enrichment/circularity audit add real originality. Novelty is not higher because the work is a benchmark and synthesis contribution within a single-position regime, not a new biological theory or prospectively validated detection system.

G: Practical value is credible but bounded. The strongest practical anchor is HIV-1 Layer-A-disjoint escape enrichment, with 37/45 novel positions and about 7-fold enrichment, which is useful for prioritizing finite wet-lab budgets. The deduction is substantial because practical value currently means retrospective search-space reduction, not calibrated prospective prediction, and the escape audit covers only 3/11 pathogens.

H: Clarity has improved through evidence ledgers, scope ledgers, and repeated non-deployability statements. The manuscript is technically readable for a committee member who follows computational biology and viral evolution. It remains dense, internally repetitive, and sometimes difficult to track across Stage 1/2/3, Wave, Cycle, and audit terminology.

I: Limitations awareness is the strongest dimension. The manuscript directly acknowledges Layer A heterogeneity, curation reproducibility limits, small-cluster inference, winner's curse, prospective validation failure, label-provenance sensitivity, dual-use risk, and adaptive-selection failure. The limitations are not merely listed; many are quantified and incorporated into the claim boundaries.

J: Overall maturity is good and defense-ready with revision rather than reconstruction. The work now has a stable thesis: MutBench is a retrospective triage benchmark showing pathogen-dependent information utility and bounded practical enrichment, while rejecting deployable adaptive selection at n=11. Remaining maturity concerns are external reproduction, independent label recuration, prospective validation, and simplification of the narrative spine.

## Strongest single deduction
one-line: G, practical value remains retrospective and anchored mainly by HIV-1; fix by adding an externally validated prospective or time-forward escape-prioritization study on an expanded pathogen panel.

RESULT_PROF_V7_01: total=81.7/100 min_item=7.6(G) max_item=9.0(I)
